LB Pharmaceuticals Inc (LBRX)
Nasdaq · Healthcare · Biotechnology
$34.62−6.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- P/E (trailing)
- 346.2
- 52-week range
- $14.32 – $50.16
- 52-week change
- +144.32%
- EPS (trailing)
- $0.10
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$25.2M
- Diluted EPS
- −$3.13
- Free cash flow
- −$35.3M
From the company’s annual report on SEC EDGAR.
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Headquarters: New York, United States · 49 employees · lbpharma.us